Sage Journals: Discover world-class research

Abstract

Keywords

pediatric prurigo nodularis oral tofacitinib JAK inhibitors tofacitinib prurigo

Get full access to this article

View all access options for this article.

References

Huang

Roh

Sutaria

, et al. Real-world disease burden and comorbidities of pediatric prurigo nodularis. J Am Acad Dermatol. 2022;86:655-657. doi:10.1016/j.jaad.2021.02.030

Yiling

Ali

Jiayang

, et al. Effectiveness of dupilumab in pediatric patients with prurigo nodularis-like atopic dermatitis. Dermatitis. 2023;34(2):162-163. doi:10.1089/derm.2022.29008.yyi

Kyvayko

Fachler-Sharp

Greenberger

Horev

Molho-Pessach

Characterisation of paediatric prurigo nodularis: a multicentre retrospective, observational study. Acta Derm Venereol. 2024;104:adv15771. doi:10.2340/actadv.v104.15771

Gowda

Ameta

Garg

Behera

Successful use of tofacitinib in paediatric prurigo nodularis: a report of four cases. Indian J Dermatol. 2025;70(2):102-104. doi:10.4103/ijd.ijd_842_24

Yew

Yeo

PM.

Comparison between dupilumab and oral Janus kinase inhibitors in the treatment of prurigo nodularis with or without atopic dermatitis in a tertiary care center in Singapore. JAAD Int. 2023;13:13-14. doi:10.1016/j.jdin.2023.06.005

Therapeutic Efficacy of Oral Tofacitinib in Pediatric Prurigo Nodularis: A Case Series With a Review of Literature

Abstract

Keywords

Get full access to this article

References